Vyzulta (soln)
| Vyzulta (soln) | |
|---|---|
| DOSAGE | 1 gtt QPM |
| GENERIC | Latanoprostene bunod 0.024% |
| SIZE | 2.5 mL, 5 mL |
| INDICATIONS | Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. |
| MECHANISM OF ACTION | Increasing aqueous outflow |
| MICROBIOLOGY | prostaglandin / nitric oxide (NO)-donor | Latanoprostene bunod is thought to lower intraocular pressure by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. |
| CONTRAINDICATIONS & WARNINGS | Increase in pigmentation of the iris and periorbital tissues, increase in length of eyelashes, intraocular inflammation, macular edema. Contact lenses should be removed 15 minutes prior to instillation of Vyzulta |
| PEDIATRIC USE | Use in pediatric patients aged 16 years and younger is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use. |
| PREGNANCY | There are no available human data for the use of VYZULTA during pregnancy to inform any drug associated risks. |
| NOTE | |